Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-PKD: AZD1613 in Autosomal Dominant Polycystic Kidney Disease
NCT07228364Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- May 2027
- Countries
- 3
01
Overview
Phase 1, randomised, single-blind trial of AZD1613 in autosomal dominant polycystic kidney disease (ADPKD) (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 27 weeks, Change From Baseline in Safety 12-Lead ECG QTcF at 27 weeks and 18 more. Started Nov 2025; status: recruiting.
02
Drugs
AZD1613
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07228364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228364.